Search

A high rate of genetic and antigenic variability among porcine reproductive and respiratory syndrome viruses (PRRSVs) hampers effective prevention and control of the disease caused by PRRSV. The major envelope protein (GP5) encoded by the ORF5 of PRRSV has a critical role in inducing virus neutralizing (VN) antibody and cross protection among different strains of PRRSV. This study was conducted to identify sequence elements related to cross neutralization by comparing the ORF5 sequences of 69 field isolates in conjunction with their susceptibility to VN antibody raised against the VR2332 strain in vitro and in vivo . Five common variable sites (amino acid position 32–34, 38–39, 57–59, 137 and 151) were identified between susceptible and resistant viral isolates. Mutants whose ORF5 amino acid sequences were substituted with the sequences corresponding to the 5 identified common variable sites individually or concurrently were generated from a VR2332-backboned infectious clone by site mutagenesis. The change in the susceptibility of the mutants to VN antibodies specific for VR2332 or a heterologous PRRSV was assessed to determine the association of those 5 identified sites with cross neutralization. Among the five sites, the changes of amino acid sequences at three sites (32–34, 38–39, and 57–59) located in the N-terminal ectodomain of ORF5 significantly influenced the susceptibility of the mutant viruses to VN antibody, suggesting that sequence homology at these sites can be utilized as genetic markers to predict the degree of cross neutralization among different PRRSVs.

The classical swine fever (CSF) vaccine, which is derived from the LOM strain of the CSF virus (CSFV), induces protective immunity against CSFV infection. However, several factors influence vaccine efficacy. Evidence suggests that infection by porcine reproductive and respiratory syndrome virus (PRRSV) and/or porcine circovirus 2 (PCV2) reduces the efficacy of several vaccines. Here, we examined the effect of PRRSV or PCV2 alone or co-infection by PRRSV/PCV2 on the potency of the LOM vaccine in pigs. Neither CSFV antibody levels nor the period during which CSFV antigens were detectable in LOM-vaccinated pigs were negatively affected by infection by PRRSV or PCV2. However, co-infection with PRRSV/PCV2 may affect the replication or activity of the CSF vaccine virus in pigs vaccinated with the LOM strain, although CSFV antibody levels were not negatively affected. Nevertheless, the LOM vaccine afforded complete protection against a virulent strain of CSFV.